Leqembi side effects can include headache, infusion-related reactions, and a brain MRI finding called ARIA. That does not mean everyone will have severe problems, but it does mean treatment is more monitored than a routine infusion. If you or a caregiver know what symptoms matter, what MRI checks are for, and when to contact the neurology team, treatment tends to feel less uncertain.
Leqembi, or lecanemab, is an IV monoclonal antibody, a lab-made immune protein used in certain people with early Alzheimer’s disease. Its goal is to slow disease progression, not create an immediate day-to-day boost, so safety tracking is a major part of treatment from the first infusion onward.
Prescription details may be confirmed with the prescriber when required.
Key Takeaways
- Common problems: headache and infusion-related symptoms are well known.
- MRI monitoring: ARIA can appear on scans before symptoms show up.
- Urgent warning signs: new confusion, vision change, trouble walking, seizures, or breathing trouble need fast review.
- Response takes time: benefit is judged over months, not after one infusion.
Why it matters: Some important treatment risks may appear on MRI before they feel obvious day to day.
Leqembi Side Effects: The Main Patterns to Know
The main Leqembi side effects most patients hear about are infusion-related reactions, headache, and ARIA. Those effects do not all carry the same weight. Chills or nausea during an infusion are unpleasant but often manageable. ARIA, by contrast, is a monitored brain finding that may need added imaging or a treatment pause.
That difference is why the safety conversation around this medicine can sound more complicated than with a standard IV drug. Your care team is watching for two things at once: how you feel and what MRI scans show. A person may feel fine and still need follow-up imaging, or may feel unwell after an infusion without having ARIA. Both patterns matter.
Many cases of ARIA are found before they cause clear symptoms. Even so, new neurologic changes should never be brushed off as routine aging, dehydration, or a bad day. Context matters: when the symptom started, whether it followed an infusion, whether it is worsening, and whether it comes with confusion, vision change, or trouble walking.
| Pattern | What it can feel like | Why the team watches it |
|---|---|---|
| Infusion reaction | Chills, feverish feeling, dizziness, nausea, body aches, flushing | Often happens during or soon after infusion and may change how the visit is managed |
| Headache | Pressure, aching, or worsening head pain | Can be mild, but a new severe headache may need closer review |
| ARIA | Sometimes no symptoms; sometimes headache, confusion, vision change, gait change, nausea, or seizure | Needs MRI-based monitoring because it can be serious |
| Allergic reaction | Hives, facial swelling, lip or tongue swelling, breathing difficulty | Needs urgent medical assessment |
Not every headache or dizzy spell means something dangerous. The key question is whether the symptom fits a short-lived infusion reaction or a pattern that suggests a neurological complication. That is why symptom logs, follow-up calls, and scheduled MRI scans all matter.
What to Expect on Infusion Day
A treatment day is usually built around observation, not just drug delivery. Before the IV starts, the team may review recent symptoms, prior MRI results, and any new medicines. During the infusion, staff watch for early reaction signs such as chills, nausea, dizziness, feeling flushed, throat discomfort, or shortness of breath.
During the infusion
Most people are not asked to do anything complex. The useful job is to speak up early if you feel different. A scratchy throat, new headache, shakiness, body aches, or a sense that something is off is easier to assess when reported right away. Early reporting gives the infusion team more room to respond during the visit.
If you are a caregiver, your role can also be practical. You may notice a change in alertness, balance, or facial expression before the patient mentions it. That kind of observation can help the team decide whether the symptom fits a typical infusion reaction or something that needs more review.
After you go home
Symptoms can also appear later the same day or after you leave. Headache, chills, nausea, dizziness, and feeling washed out may settle with time, but they should still be documented and reported according to your care team’s instructions. That record helps distinguish a one-time infusion reaction from a recurring pattern that may affect later visits.
Early infusions often involve closer attention because reactions may show up then. That does not mean later visits are risk-free. New symptoms at any point in treatment deserve the same careful review.
Quick tip: Write down when symptoms began, how long they lasted, and whether they started during or after the infusion.
Where permitted, dispensing is handled by licensed third-party pharmacies.
Understanding ARIA and MRI Monitoring
ARIA is the safety issue that makes this treatment different. The term stands for amyloid-related imaging abnormalities, a label for brain changes seen on MRI that can involve swelling or small areas of bleeding. Many cases are mild and found on scheduled scans before the person notices anything unusual.
That is why MRI monitoring is not an extra formality. It is part of treatment itself. A baseline MRI is usually done before therapy starts, and repeat scans are commonly scheduled during the early phase of treatment. If symptoms raise concern, the neurology team may order another MRI sooner.
Symptoms that deserve fast review
Possible ARIA symptoms can include new or worsening headache, confusion, dizziness, vision change, nausea, vomiting, trouble walking, weakness, or seizures. These symptoms are not specific to ARIA alone, which is another reason they should be discussed quickly rather than self-diagnosed at home.
Risk is not the same for every person. The care team may review MRI history, other neurological conditions, and medicines that affect bleeding risk. Genetic factors may also matter. Those details help explain why one person’s monitoring plan may look more intensive than another’s.
If ARIA is found, the next step can range from continued observation to a treatment pause and closer imaging. The decision depends on the MRI findings, whether symptoms are present, and how severe they appear. This is one reason Leqembi side effects cannot be judged only by how you feel after an infusion.
Symptoms to Report Right Away
If Leqembi side effects appear between visits, contact the prescribing or infusion team quickly for any new neurologic symptom or possible allergic reaction. Do not wait for the next scheduled appointment if something feels clearly different from baseline.
- New confusion or unusual sleepiness
- Severe or worsening headache
- Vision changes
- Trouble walking or new weakness
- Seizure activity
- Hives or swelling of the face, lips, or tongue
- Shortness of breath or chest tightness
Those symptoms need urgent attention because they can signal ARIA, a significant infusion reaction, or another medical problem that needs evaluation. Severe breathing trouble, a seizure, or a sudden major neurological change should be treated as an emergency.
Less dramatic symptoms still matter. A mild headache after infusion, chills, nausea, dizziness, body aches, or a temporary flushed feeling may be less urgent, but the team should still know about them. Patterns help shape later monitoring and treatment decisions.
When you call, it helps to share four details: when the symptom started, how bad it feels now, whether it is getting better or worse, and whether it began during or after an infusion. If a caregiver is involved, their observations can be just as useful as the patient’s own report.
One practical challenge is that Alzheimer’s symptoms and treatment side effects can overlap. That makes outside observation valuable. If a caregiver notices a sharper change than usual in memory, balance, speech, or alertness, it is reasonable to report that change even if the patient downplays it.
Are These Effects Permanent?
Most Leqembi side effects are not permanent, especially routine infusion-related symptoms that fade after the visit or within a short period. Headache, chills, nausea, dizziness, and flu-like discomfort often improve rather than continue indefinitely.
But temporary does not mean trivial. A difficult reaction can still interrupt treatment, require observation, or lead to changes in the next infusion plan. ARIA works differently from a short-lived infusion reaction. It may be silent on imaging, may need repeat MRI follow-up, and can sometimes require treatment to be paused or stopped.
Whether ARIA resolves, and how quickly, varies from case to case. The key point is not to assume a symptom will simply pass. New neurologic symptoms deserve a real assessment because the next step depends on what the MRI shows and whether the symptoms are worsening.
Allergic reactions deserve the same caution. Hives, facial swelling, lip or tongue swelling, or breathing difficulty are not symptoms to watch casually at home. They need urgent medical attention.
Many people find it helpful to separate symptoms into two buckets: discomfort that should be logged and reported, and danger signs that need same-day attention. That simple distinction can reduce panic without downplaying real risk.
How Response Is Judged Over Time
Knowing whether treatment is working is usually slower and less obvious than noticing a side effect. Most people do not feel a clear immediate benefit after an infusion. The goal is to slow decline over time, so response is judged over months, not by how you feel the next morning.
Clinicians often look at memory and daily function trends, caregiver observations, clinic-based cognitive assessments, and whether treatment can continue safely. In other words, benefit and tolerability are reviewed together. A medication that fits the plan on paper may still need to be paused if side effects or MRI findings become a concern.
If treatment is interrupted, next steps are individualized. Some people need added monitoring before another infusion is considered. Others may need a broader discussion about whether the balance of benefit and risk still makes sense.
This is also why follow-up visits matter even when the infusion itself seemed uneventful. A calm treatment day does not replace MRI monitoring, and a rough infusion day does not automatically mean therapy has failed. The pattern over time is what guides decisions.
Bring a current medication list to each visit, especially if anything changed recently. The team may review medicines that affect bleeding risk or complicate symptom interpretation. A short symptom diary can also make appointments more useful.
For broader condition education, browse the Neurology Hub. If you need a separate browseable list of condition-related items, the Neurology Category is organized apart from editorial content.
Cash-pay or cross-border access can depend on eligibility and jurisdiction.
Authoritative Sources
- For official safety details from the manufacturer, see Potential side effects | LEQEMBI.
- For visit planning and infusion expectations, review What to expect at an Infusion | LEQEMBI.
- For an independent clinical summary, Mayo Clinic provides Lecanemab-irmb (intravenous route) – Side effects & uses.
Further reading: Leqembi side effects range from mild infusion symptoms to MRI-detected ARIA, so routine monitoring and timely symptom reporting are part of care, not optional extras.
This content is for informational purposes only and is not a substitute for professional medical advice.
